Aug 8 2012
Estudio diagnóstico de Parkinson
DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome
DaTscanTM (ioflupane 123I injection) US FDA-approved in January 2011, is the first FDA-approved
radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon
emissionparkinsonian computed tomography (SPECT) brain imaging to assist in the evaluation of
adult patients with suspected parkinsonian syndromes (idiopathic Parkinson’s disease,
parasupranuclear palsy (PSP) and multiple system atrophy [MSA]). When utilized with SPECT imaging,
DaTscan, administered intravenously (IV) in a single dose, can detect the presence of functional
domaminergic neurons in the striatum of those patients with clinically uncertain parkinsonian
syndromes (PS). The product is designed to assist the clinician in the differential diagnosis of tremor
associated with PS vs. essential tremor (ET). DaTscan is not designed to differentiate among the
parkinsonian syndromes.